An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats.
Human metapneumovirus (hMPV) is a recently discovered paramyxovirus that causes upper and lower respiratory tract infections in infants, the elderly, and immunocompromised individuals worldwide. Here, we developed Venezuelan equine encephalitis virus replicon particles (VRPs) encoding hMPV fusion (F) or attachment (G) glycoproteins and evaluated the immunogenicity and protective efficacy of these vaccine candidates in mice and cotton rats. VRPs encoding hMPV F protein, when administered intranasally, induced F-specific virus-neutralizing antibodies in serum and immunoglobulin A (IgA) antibodies in secretions at the respiratory mucosa. Challenge virus replication was reduced significantly in both the upper and lower respiratory tracts following intranasal hMPV challenge in these animals. However, vaccination with hMPV G protein VRPs did not induce neutralizing antibodies or protect animals from hMPV challenge. Close examination of the histopathology of the lungs of VRP-MPV F-vaccinated animals following hMPV challenge revealed no enhancement of inflammation or mucus production. Aberrant cytokine gene expression was not detected in these animals. Together, these results represent an important first step toward the use of VRPs encoding hMPV F proteins as a prophylactic vaccine for hMPV.
Mok
Hoyin
H
Departments of Pediatrics, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee 37232, USA.
Tollefson
Sharon J
SJ
Podsiad
Amy B
AB
Shepherd
Bryan E
BE
Polosukhin
Vasiliy V
VV
Johnston
Robert E
RE
Williams
John V
JV
Crowe
James E
JE
D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002460:Cell Line; D004666:Encephalitis Virus, Venezuelan Equine / Q000235:genetics; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000097:blood; D008168:Lung / Q000473:pathology / Q000821:virology; D008253:Macaca mulatta; D029121:Metapneumovirus / Q000276:immunology*; D051379:Mice; D008811:Mice, Inbred DBA; D009092:Mucous Membrane / Q000276:immunology; D009500:Neutralization Tests; D018184:Paramyxoviridae Infections / Q000517:prevention & control*; D051381:Rats; D012137:Respiratory System / Q000821:virology; D016205:Sigmodontinae; D015678:Viral Structural Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
D000914:Antibodies, Viral; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D015678:Viral Structural Proteins; D014765:Viral Vaccines
J Virol. 2007 Dec;81(24):13412-23
17913817
J Gen Virol. 2004 Jun;85(Pt 6):1655-1663
15166450
J Infect Dis. 2005 Sep 15;192(6):1061-5
16107960
J Infect Dis. 2004 Apr 15;189(8):1388-96
15073675
Virology. 2003 Oct 10;315(1):1-9
14592754
Virology. 1997 Dec 22;239(2):389-401
9434729
Nat Immunol. 2001 Aug;2(8):732-8
11477410
J Infect Dis. 2005 Oct 1;192(7):1149-53
16136455
Virus Res. 2003 May;93(1):51-62
12727342
J Virol. 1996 May;70(5):2852-60
8627759
J Virol. 2003 Jul;77(13):7486-91
12805448
J Immunol. 1987 Nov 15;139(10):3484-92
2824609
J Virol. 2005 Oct;79(19):12608-13
16160190
Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):8996-9001
15956195
J Infect Dis. 2002 Nov 1;186(9):1330-4
12402203
J Virol. 2006 Feb;80(4):2034-44
16439559
Vaccine. 2005 Feb 25;23(14):1657-67
15705469
J Infect Dis. 2003 Mar 1;187(5):785-90
12599052
J Virol. 2007 Oct;81(19):10329-39
17652394
J Virol. 2007 Oct;81(20):11461-7
17670840
Immunity. 2001 Oct;15(4):637-46
11672545
Lancet. 2003 Mar 15;361(9361):890-1
12648965
Virology. 2006 Feb 20;345(2):492-501
16300813
J Virol. 2004 Dec;78(23):12877-87
15542640
J Virol. 1991 Mar;65(3):1634-7
1995956
Emerg Infect Dis. 2002 Sep;8(9):976-8
12194777
J Clin Microbiol. 2004 Dec;42(12):5944-6
15583349
J Virol. 2007 Dec;81(24):13710-22
17928349
J Immunol. 2001 Oct 1;167(7):3910-8
11564809
Infect Immun. 2006 Mar;74(3):1612-20
16495532
J Virol. 2005 Sep;79(17):10944-51
16103146
J Virol. 2004 Jul;78(13):6927-37
15194769
J Virol. 2006 Jun;80(12):5854-61
16731924
N Engl J Med. 2004 Jan 29;350(5):443-50
14749452
J Exp Med. 1988 Sep 1;168(3):1163-8
3262705
Vaccine. 2007 Jun 28;25(27):5034-40
17543425
J Virol. 2007 Jan;81(2):698-707
17050599
J Virol. 2002 Oct;76(20):10203-10
12239295
J Infect Dis. 2004 Jul 1;190(1):20-6
15195239
J Virol. 2003 Oct;77(20):10819-28
14512532
Nat Med. 2001 Jun;7(6):719-24
11385510
Infect Immun. 1980 Mar;27(3):862-6
6155338
Emerg Infect Dis. 2004 Apr;10(4):658-66
15200856
J Infect Dis. 2006 Feb 1;193(3):387-95
16388486
J Gen Virol. 2007 Apr;88(Pt 4):1251-1259
17374769
Vaccine. 1994 Jun;12(8):731-5
8091852
Emerg Infect Dis. 2004 Jun;10(6):1154-7
15207075
J Clin Microbiol. 2004 Aug;42(8):3532-7
15297494
J Virol. 1985 Sep;55(3):517-20
4020957
Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3722-7
16505353
Clin Vaccine Immunol. 2012 Oct;19(10):1651-60
22914365